Gastroenterology and Liver

Pharmacology & Novel Therapeutics

Pharmacological innovations continue to transform gastroenterology and hepatology, offering new avenues for disease management. This session will focus on recent advances in biologics, small molecule inhibitors, immunotherapies, and combination therapies for conditions such as IBD, liver fibrosis, and GI cancers. Participants will review mechanisms of action, clinical trial results, safety profiles, and therapeutic efficacy of emerging treatments. The track also addresses challenges in drug development, patient selection, and optimizing treatment strategies for diverse populations.

The session further emphasizes translational research and precision medicine approaches in pharmacotherapy. Novel drug delivery systems, repurposed medications, and combination regimens will be discussed for their potential to improve patient outcomes. Participants will also explore regulatory frameworks, cost-effectiveness considerations, and strategies to integrate new therapies into clinical practice. This track provides an interactive platform for clinicians, researchers, and industry professionals to share findings, present ongoing trials, and discuss the future of therapeutics in gastroenterology and hepatology.